Vertex Offers Cystic Fibrosis Patients A Chance To Breathe Easier
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While most attention has been on Vertex Pharmaceuticals' hepatitis C drug telaprevir, which is widely expected to gain FDA approval in May, the company has also been steadily progressing on its investigational cystic fibrosis agents, and it may have lined up another home run.